Author(s):
Bhairavi Vijayanand Saraf, Preeti Rajeev Mehta, Rahul Subhash Somani
Email(s):
saraf.bhairavi@gmail.com
DOI:
10.52711/2231-5675.2026.00011 
Address:
Bhairavi Vijayanand Saraf1*, Preeti Rajeev Mehta1, Rahul Subhash Somani2
1Department of Chemistry, Faculty of School of Basic and Applied Sciences, Sangam University, Bhilwara (Rajasthan) - 311001 India.
2Alkem Laboratories Limited, Mumbai 400013
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2026
ABSTRACT:
Vonoprazan is a potassium-competitive acid blocker widely used for the management of acid-related gastrointestinal disorders. Although the chemical structures of vonoprazan have been elucidated, a systematic toxicological evaluation has not been reported in public literature. In the present study, an in-silico toxicological risk assessment was conducted for two major degradation products of vonoprazan namely N-dealkylated vonoprazan (DP1) and vonoprazan aldehyde (DP2) using QSAR methodologies recommended under ICH M7(R2) for mutagenicity assessment, along with additional evaluation of other toxicity endpoints for broader toxicological understanding. A complementary quantitative structure-activity relationship (QSAR) strategy was employed, as recommended under ICH M7(R2), integrating statistical-based predictions (ADMETlab), expert rule-based structural alert analysis (ToxTree), and additional consensus modeling using the Online Chemical Modeling Environment (OCHEM). Mutagenicity, carcinogenicity, and selected organ toxicity endpoints were evaluated for the intact degradation products as well as relevant structural fragments. DP1 was consistently predicted to be non-mutagenic and non-carcinogenic across all applied models and was therefore classified as an ICH M7 Class 5 (non-mutagenic) impurity, permitting control under standard ICH Q3B(R2) limits. In contrast, DP2 triggered structural alerts for potential genotoxicity due to the presence of an aldehyde functionality and was classified as an ICH M7 Class 3 impurity. However, in-silico metabolic assessment indicated rapid oxidation of DP2 to the corresponding carboxylic acid metabolite, which was devoid of genotoxic and carcinogenic alerts, supporting a mitigated toxicological risk. This study establishes a robust, toxicological framework aligned with ICH M7(R2) principles for mutagenicity assessment for the safety evaluation and control of vonoprazan degradation products and provides a scientifically justified basis for impurity specification setting and regulatory risk management in pharmaceutical development.
Cite this article:
Bhairavi Vijayanand Saraf, Preeti Rajeev Mehta, Rahul Subhash Somani. Integrated In-Silico Toxicological Risk Assessment of Vonoprazan Degradation Products using Complementary QSAR Approaches. Asian Journal of Pharmaceutical Analysis. 2026; 16(2):81-8. doi: 10.52711/2231-5675.2026.00011
Cite(Electronic):
Bhairavi Vijayanand Saraf, Preeti Rajeev Mehta, Rahul Subhash Somani. Integrated In-Silico Toxicological Risk Assessment of Vonoprazan Degradation Products using Complementary QSAR Approaches. Asian Journal of Pharmaceutical Analysis. 2026; 16(2):81-8. doi: 10.52711/2231-5675.2026.00011 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2026-16-2-1
REFERENCES:
1. U.S. National Library of Medicine. DailyMed: Vonoprazan fumarate [Internet]. Bethesda (MD): National Institutes of Health; [cited 2025 May 10]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cc52ac5-77ec-4d66-a770-762a1a960914
2. Liu L, Cao N, Ma X, Xiong K, Sun L, Zou Q. Identification, characterization, and high-performance liquid chromatography quantification of process-related impurities in vonoprazan fumarate. J Sep Sci. 2016; 39(7): 1232–41. doi:10.1002/jssc.201501154
3. Luo Z, Liu A, Liu Y, Wang G, Chen X, Wang H, et al. Development of a stability-indicating HPLC method for simultaneous determination of ten related substances in vonoprazan fumarate drug substance. J Pharm Biomed Anal. 2018; 149: 133–42. doi: 10.1016/j.jpba.2017.11.011
4. Kanaan BM, Algohary AM, Ibrahim AM. Optimized reversed-phase liquid chromatography methodology for the determination of vonoprazan fumarate impurities: towards Six Sigma quality standards and sustainability assessment. Microchem J. 2024; 206: 111535. doi: 10.1016/j.microc.2024.111535
5. Abuothman M, Deeb AA, Hailat M, Abuyaman O, Aldoqum HM. A novel fast analytical method for the determination of N-nitroso vonoprazan in vonoprazan tablets and raw materials using LC-ESI-MS/MS. Int J Environ Anal Chem. 2024; 104(9): 1–100. doi:10.1080/03067319.2024.2407916
6. Qiao Y, Huang J, Xu Y, Zhao J, Wang Q. Determination of vonoprazan pyroglutamate and vonoprazan fumarate by HPLC. China Pharmacist. 2018; 12: 535–8.
7. Abdelazim AH, Abdel-Fattah A, Osman AO, Abdel-Kareem RF, Ramzy S. Spectrophotometric quantitative analysis of aspirin and vonoprazan fumarate in recently approved fixed-dose combination tablets using ratio spectra manipulating tools. J AOAC Int. 2023; 106(2): 490–5. doi:10.1093/jaoacint/qsac128
8. Saleh AM, El-Kosasy AM, Fares NV. UV spectrophotometric method development and validation of vonoprazan fumarate in bulk and pharmaceutical dosage form; green profile evaluation via eco-scale and GAPI tools. Egypt J Chem. 2023; 66(8): 141–8. doi:10.21608/ejchem.2022.161704.6948
9. Alzaghal NM, El-Mossalamy ES, El-Sayed GO. Method development and validation for estimation of vonoprazan by RP-HPLC method in bulk and tablets dosage form. Egypt J Chem. 2024;67(2):145–59. doi:10.21608/ejchem.2023.193129.7593
10. Salva C, Galla R. Development and validation of a stability-indicating RP-UPLC method for the simultaneous estimation of clarithromycin, amoxicillin, and vonoprazan in a physical mixture. J Appl Pharm Sci. 2024; 14(5): 193–202. doi:10.7324/JAPS.2024.165836
11. Moneim MM, Hamdy M. Chromatographic assay of recently approved co-formulation of vonoprazan fumarate with low-dose aspirin: AGREE, Complex MoGAPI, and RGB 12-model assessments. BMC Chem. 2024; 18(1): 230. doi:10.1186/s13065-024-01344-7
12. Ali NAM, El-Gindy AE, Wahba MEK, Mostafaa AE. Ecofriendly chromatographic method for the separation and quantification of vonoprazan fumarate, a novel potassium-competitive acid blocker with amoxicillin and clarithromycin effective in the treatment of Helicobacter pylori. Acta Chromatogr. 2025; 37: 1–13. doi:10.1556/1326.2025.01306
13. Yoneyama T, Teshima K, Jinno F, Kondo T, Asahi S. A validated simultaneous quantification method for vonoprazan (TAK-438F) and its four metabolites in human plasma by liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2016; 1015–16:42–9. doi: 10.1016/j.jchromb.2016.01.051
14. Saraya RE, Hassan YF, Eltukhi WE, Salman BI. Ultra-sensitive fluorimetric method for estimation of vonoprazan in human plasma and content uniformity test. J Fluoresc. 2022; 32(5): 1725–32. doi:10.1007/s10895-022-02979-2
15. Chen X, Chen T, Huang Y, Wang M, Wang Y, Wu P, et al. LC–MS/MS method for rapid detection of vonoprazan fumarate in human plasma: development, validation and application to a bioequivalence study. Biomed Chromatogr. 2024;38(6): e5860. doi:10.1002/bmc.5860
16. El-Hamd MA, El-Maghrabey M, Magdy G, Soltan OM, Abdelrahman KS, Obaydo RH, et al. Factorial design-aided derivatization-free fluorimetric ultrasensitive assay of vonoprazan: application in uniformity of dosage units and plasma samples analysis. Microchem J. 2024; 205: 111320. doi: 10.1016/j.microc.2024.111320
17. Gupta A, Yadav J, Rawat S, Gandhi M. Method development and hydrolytic degradation study of doxofylline by RP-HPLC and LC-MS/MS. Asian J Pharm Anal. 2011; 1(1): 14–8.
18. Kasad PA, Muralikrishna KS. Method development and acid degradation study of rivaroxaban by RP-HPLC in bulk. Asian J Pharm Anal. 2013; 3(2): 62–5.
19. Gupta A, Rawat S, Gandhi M, Yadav J. Method development and acid degradation study of doxofylline by RP-HPLC and LC-MS/MS. Asian J Pharm Anal. 2011; 1(1): 10–3.
20. Gupta A, Rawat S, Pandey A. Method development and photolytic degradation study of doxofylline by RP-HPLC and LC-MS/MS. Asian J Pharm Anal. 2011; 1(2): 29-33.
21. International Council for Harmonisation (ICH). Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH; 2003.
22. International Council for Harmonisation (ICH). Q1B: Photostability testing of new active substances and medicinal products [Internet]. Geneva: ICH; 1998 [cited 2025 May 10]. Available from: https://www.ich.org
23. International Council for Harmonisation (ICH). Q2(R1): Validation of analytical procedures: text and methodology [Internet]. Geneva: ICH; 2005 [cited 2025 May 10]. Available from: https://www.ich.org
24. Arous B, Al-Mardini MA, Ghazal H, Al-Lahham F. Stability-indicating method for the determination of rivaroxaban and its degradation products using LC-MS and TLC. Res J Pharm Technol. 2018; 11(1): 212–20. doi:10.5958/0974-360X.2018.00040.9
25. Manasa M, Aanandhi VM. Stability-indicating method development and validation of semaglutide by RP-HPLC in pharmaceutical substance and product. Res J Pharm Technol. 2021; 14(3): 1385–9. doi:10.5958/0974-360X.2021. 00247.X
26. Maruthi R, Chandan RS, Tengli A. LC-MS/MS and NMR characterization of impurities in epalrestat. Res J Pharm Technol. 2021; 14(1): 11–3. doi:10.5958/0974-360X.2021.00003.2
27. Patel RA, Patel MP, Shah HR, Shah N. Development and validation of stability-indicating high-performance liquid chromatographic method for indapamide. Asian J Pharm Technol. 2015;5(3):158–64. doi:10.5958/2231-5713.2015.00023.9
28. Chandana OSS, Ravichandra Babu R. Stability-indicating HPLC method development and validation for thalidomide and its impurity determination. Asian J Pharm Anal. 2016; 6(2): 115–8. doi:10.5958/2231-5675.2016. 00017.X
29. Patil S, Amurutkar S, Upasani C. Development and validation of stability-indicating RP-HPLC method for empagliflozin. Asian J Pharm Anal. 2016; 6(4): 201–6. doi:10.5958/2231-5675.2016.00030.2
30. Patel Y, Noolvi MN, Raj H, Patel M. Development and validation of a stability-indicating RP-HPLC method for estimation of donepezil HCl from bulk drug. Asian J Pharm Clin Res. 2015; 8(1): 14–8. doi:10.5958/2231-5691.2015.00014.3
31. Housheh S. Development of a rapid, simple and stability-indicating method for determination of azithromycin using RP-HPLC. Asian J Pharm Clin Res. 2017; 10(1): 9–13. doi:10.5958/2231-5691.2017.00009.0
32. Shinde N, Bangar B, Deshmukh S, Sulake S, Sherekar D. Pharmaceutical forced degradation studies with regulatory consideration. Asian J Res Pharm Sci. 2013; 3(4): 178–88.
33. Roge AB, Tarte PS, Kumare MM, Shendarkar GR, Vadvalkar SM. Forced degradation study: an important tool in drug development. Asian J Pharm Res. 2013; 3(4): 198–201.
34. Pharmaffiliates. Vonoprazan impurities [Internet]. [cited 2025 May 30]. Available from: https://www.pharmaffiliates.com/en/parentapi/vonoprazan-impurities
35. SynZeal Research Pvt Ltd. Vonoprazan reference standards and impurities [Internet]. [cited 2025 May 30]. Available from: https://www.synzeal.com/en/vonoprazan
36. Brambilla G, Martelli A. Genotoxic and carcinogenic risks from sulfoxides and sulfones. Mutat Res Rev Mutat Res. 2009; 681(2–3): 135–47. doi: 10.1016/j.mrrev.2006.09.003
37. European Medicines Agency (EMA). Impurities: Guideline for residual solvents and degradation products [Internet]. London: EMA; 2011 [cited 2025 May 10]. Available from: https://www.ema.europa.eu
38. Saraf BV, Mehta PR, Somani RS. Development and Validation of a Stability-Indicating HPLC Method for Vonoprazan with LC-MS Characterization of Degradation Products. Research Journal of Pharmacy and Technology. 2026 (Accepted, In Press).
39. International Council for Harmonisation (ICH). M7(R2): Assessment and control of DNA-reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk [Internet]. Geneva: ICH; 2017 [cited 2025 May 10]. Available from: https://www.ich.org.
40. International Council for Harmonisation (ICH). Q3B(R2): Impurities in new drug products [Internet]. Geneva: ICH; 2006 [cited 2025 May 10]. Available from: https://www.ich.org.
41. Dobo KL, Greene N, Fred C, Glowienke S, Harvey JS, Hasselgren C, et al. In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey. Regul Toxicol Pharmacol. 2012; 62(3): 449–63. doi: 10.1016/j.yrtph.2012.01.007.
42. National Center for Biotechnology Information. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004 – [cited 2025 Dec 13]. Available from: https://pubchem.ncbi.nlm.nih.gov/ .
43. ADMETlab 3.0. Evaluation Module [Internet]. Xiangya School of Pharmaceutical Sciences, Central South University; 2024 [cited 2025 Dec 13]. Available from: https://admetlab3.scbdd.com/server/evaluation.
44. ADMETlab 3.0. Screening Module [Internet]. Xiangya School of Pharmaceutical Sciences, Central South University; 2024 [cited 2025 Dec 13]. Available from: https://admetlab3.scbdd.com/server/screening.
45. Ideaconsult Ltd. ToxTree: Toxic Hazard Estimation by Decision Tree Approach (v3.1.0) [Computer Software]. SourceForge; 2018 [cited 2025 Dec 13]. Available from: http://toxtree.sourceforge.net.
46. Sushko I, Novotarskyi S, Körner R, Pandey AK, Rupp M, Teetz W, et al. Online chemical modeling environment (OCHEM): web platform for data mining, modeling and molecular properties prediction. J Comput Aided Mol Des. 2011; 25(6): 533–54. [Available from: https://ochem.eu/login/show.do]